ArticleScientific reports2025
Rapid preparation of bioactive composites for transforaminal lumbar interbody fusion.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bone Growth Stimulators to Enhance Spinal Fusion Outcomes.Spine surgery and related research · 2026Review
- Mechanobiology of intervertebral disc degeneration: From pathological mechanisms to therapeutic approaches.Mechanobiology in medicine · 2025Review
- Prolonged irrigation time in endoscopic aqueous medium impairs MSC/β-TCP adhesion and osteogenic potential.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The current stem cell tissue engineering always requires in vitro cell culture. To solve this problem, the bone mesenchymal stem cells (MSCs) screen-enrich-combine circulating system (SECCS) was created to rapidly enrich stem cells and combined with β-tricalcium phosphate (β-TCP) to immediately produce bioactive MSCs/β-TCP composites. 37 patients who underwent transforaminal lumbar interbody fusion (TLIF) surgery were included in this study and randomly divided into two groups. One group uses laminal bone grafts (LBG) for intervertebral fusion, and another group uses MSCs/β-TCP composites. The new technique could quickly and selectively enrich stem cells from the bone marrow and simultaneously implant them into the intervertebral space during operation. The cells eluted from the β-tricalcium phosphate were confirmed to be stem cells based on their characteristics. Higher early fusion rates, similar intervertebral height decreases, and functional improvement tendencies were observed in the SECCS group when compared to the LBG group. The bioactive scaffold prepared by SECCS showed better osteogenic efficiency at the early stage of intervertebral fusion compared to autologous LBG, which provided a new bone scaffold substitute for autologous bone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.